Rigel has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to ...

Tris Pharma has reported positive outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol to treat moderate-to-severe ...

Intellia aims to submit a biologics license application in 2026. Credit: Piotr Swat/Shutterstock. Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III ...

SalubrisBio shared interim results from an ongoing Phase II heart failure trial examining its recombinant antibody fusion protein, JK07.

The US company said that results from the Alpha-CORRECT trial saw its colon cancer diagnostic Oncodetect achieving a ...

Clinical research company Advarra has introduced Study Collaboration, a solution designed to expedite study startup by ...

The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.

Amylyx will be allowed to run a Phase I trial after the FDA lifted a clinical hold of its investigational ALS drug.

Synthetic chemicals called per- and polyfluoroalkyl substances (PFAS) have been accumulating in the environment since their ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia SAD study of the oral tablet, ASC30, in obese ...

Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

YolTech Therapeutics is set to commence a trial of its in vivo gene editing therapy, YOLT-204, aimed at treating TDT.